Attruby (Acoramidis) for Amyloidosis

Overview
Attruby is an FDA-approved medication used to treat cardiomyopathy caused by wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults. It helps reduce the risk of heart-related death and hospitalizations. ATTR-CM is a condition where amyloid proteins build up in the heart, causing damage over time. To use this treatment, individuals must have a confirmed diagnosis of ATTR-CM. Attruby is also known by its drug name, acoramidis.

Attruby is believed to work by stabilizing the transthyretin protein. This prevents the protein from breaking into smaller pieces that form harmful amyloid deposits, helping to slow heart damage and related symptoms.

How do I take it?
Attruby comes as oral tablets. It is usually taken as two tablets, twice a day. The tablets can be taken with or without food, but they should be swallowed whole — do not cut, crush, or chew them. Always take Attruby as directed by your health care provider.

Side effects
According to the prescribing label, common side effects include diarrhea and mild stomach pain. 

Rare but more serious side effects can include temporary increases in creatinine (a marker of kidney function) and a decrease in epidermal growth factor receptor (eGFR, a measure of kidney filtering).

For more information about this treatment, visit:

Attruby (Acoramidis) Tablets, for Oral Administration — U.S. Food and Drug Administration

Attruby FDA Approval History — Drugs.com